Covered recipient · General Payments record
KATHLEEN E LAMBERT
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$92,064.59
- Reported across 164 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,600.00 | 5 |
| Food and Beverage | $1,246.19 | 54 |
| Travel and Lodging | $29.48 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $6,820.32 | 13 |
| Merck Sharp & Dohme Corporation | $131.62 | 5 |
| Daiichi Sankyo Inc. | $97.57 | 4 |
| JAZZ PHARMACEUTICALS INC. | $85.25 | 3 |
| Celgene Corporation | $82.03 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $59.23 | 2 |
| PFIZER INC. | $54.15 | 3 |
| ABBVIE INC. | $53.02 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $41.93 | 2 |
| Gilead Sciences, Inc. | $41.86 | 2 |
| Acerta Pharma LLC | $38.70 | 2 |
| Tempus AI, Inc | $36.05 | 2 |
| ARRAY BIOPHARMA INC | $35.30 | 2 |
| AVEO Pharmaceuticals, Inc. | $32.90 | 1 |
| Astellas Pharma US Inc | $25.98 | 1 |
| Alexion Pharmaceuticals, Inc. | $25.69 | 1 |
| BeiGene USA, Inc. | $25.34 | 1 |
| ImmunoGen, Inc. | $22.84 | 1 |
| Genentech USA, Inc. | $21.16 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $20.56 | 1 |
| Stemline Therapeutics Inc. | $20.06 | 1 |
| Rigel Pharmaceuticals, Inc. | $19.89 | 1 |
| Legend Biotech USA Inc. | $19.37 | 1 |
| Deciphera Pharmaceuticals Inc. | $17.82 | 1 |
| PharmaEssentia USA Corporation | $15.89 | 1 |
| Incyte Corporation | $15.57 | 1 |
| Sumitomo Pharma America, Inc. | $15.57 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (60)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.